12 results about "Viral diarrhea" patented technology

The invention relates to a fermented traditional Chinese medicine composition for preventing and treating piglet viral diarrhea as well as a preparation method and application thereof, and relates to the technical field of livestock breeding. The feed is prepared by taking traditional Chinese medicine components as basic raw materials and adding probiotics for fermentation, and the traditional Chinese medicine components comprise the following raw materials in parts by weight: 0.5-1.5 parts of cardamine violifolia dry powder, 5-15 parts of Chinese pulsatilla root, 10-20 parts of coptis chinensis, 10-20 parts of golden cypress, 10-20 parts of ash bark, 4-8 parts of turmeric, 6-10 parts of pumpkin seeds and 4-8 parts of a ginkgo leaf extract feed additive. Through cooperation of multiple components, the immunity and antioxidant functions of the body are enhanced, the structural integrity of the intestinal tract is maintained, piglet diarrhea caused by PEDV infection is effectively relieved, and growth and development of the piglet are promoted; local specialty crops are selected as medicines, and theoretical basis and practical reference are provided for deep processing of local genuine medicinal materials and PED prevention and control.

The invention is suitable for the technical field of gene engineering, and provides 3Ag + mi3 protein nanoparticles for preventing and treating BVD and IBR as well as a preparation method and application of the 3Ag + mi3 protein nanoparticles, the 3Ag + mi3 protein nanoparticles comprise E2-1b-st protein, E2-1d-st protein, gD-st protein and mi3-sc protein; the E2-1b-st protein, the E2-1d-st protein and the gD-st protein are coupled to the surface of the same mi3-sc protein through an isopeptide bond to form 3Ag + mi3 protein nanoparticles; the amino acid sequences of the E2-1b-st protein, the E2-1d-st protein, the gD-st protein and the mi3-sc protein are respectively shown as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8 in a sequence table. After animals are immunized by the 3Ag + mi3 protein nanoparticles, an effective immune protection effect can be generated, and the 3Ag + mi3 protein nanoparticles have a good prevention and control application prospect on bovine viral diarrhea and bovine rhinotracheitis.

The invention belongs to the field of antiviral compounds, and discloses an application of a benzoylaniline compound in preparation of broad-spectrum antiviral drugs. The benzoylaniline compound has a general formula as shown in a formula I, wherein R1, R2, R3, R4 and R5 are at least one of H, C1-4 alkyl, C1-4 alkoxy, halogen, hydroxyl and nitryl; wherein H on the C1-4 alkyl group and H on the C1-4 alkoxy group are optionally substituted by halogen atoms, and the condition is that at least two of R1, R2, R3, R4 and R5 are halogens, but not more than 4; at least one of R1, R2, R3, R4 and R5 is F, but not more than 2. The compound disclosed by the invention has a relatively good in-vitro antiviral effect, and the compound BAB162 is wide in antiviral spectrum and has a remarkable inhibition effect on various viruses at low concentration. The BAB162 shows an obvious treatment effect in a piglet viral diarrhea infection model and a mouse acute hepatitis virus infection model.

This invention utilizes a machine learning model to analyze the S1-CTD region of the PEDV S protein crystal structure. Through virtual peptide screening, a peptide sequence of FWKEAK (110616) with potential affinity for the target protein was identified. The 110616 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV S1 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 110616 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 110616 sequence significantly inhibited PEDV infection.

The application discloses a porcine epidemic diarrhea, porcine delta coronavirus and porcine rotavirus triple mRNA vaccine and a preparation method thereof, the triple mRNA vaccine is prepared by mixing mRNA for expressing S, M and N proteins of porcine epidemic diarrhea virus, mRNA for expressing S, M and N proteins of porcine delta coronavirus and mRNA for expressing VP4 and VP7 proteins of porcine rotavirus with liposomes, and is applied to simultaneous prevention and immunization of porcine epidemic diarrhea, porcine delta coronavirus and porcine rotavirus. After sows are immunized by the triple mRNA vaccine, the sows can effectively activate the sows to generate specific antibodies and neutralizing antibodies, and piglets obtain passive immunoprotection by sucking the milk of the sows. Piglet challenge protection tests show that the protection rates of the triple mRNA vaccine on the three viruses are all 100% (5 / 5). The application simplifies the inoculation procedure, reduces the epidemic prevention cost, can achieve the effect of preventing and treating three kinds of porcine viral diarrhea by one injection, and provides a simple, convenient and efficient new triple vaccine for domestic farms.

The invention relates to a compound emulsion for preventing and controlling bovine viral diarrhea. Every 100 g of the compound emulsion comprises the following components by weight: 0.1 to 6.0 g of bovine viral diarrhea antibody, 2.0 to 4.0 g of solanum nigrum polysaccharide, 0.1 to 1.0 g of donaxine, 0.1 to 5.0 g of taurine, 1.0 to 3.0 g of ephedra oil, 4.0 to 10.0 g of polyoxyethylene (40) castor oil, 10.0 to 18.0 g of linoleic acid, 14.0 to 20.0 g of ethyl oleate, 15.0 to 25.0 g of span-40, and the balance of water for injection. Primary emulsion of the reemulsion is in an oil-in-water (O / W) type, and secondary emulsion of the reemulsion is in an oil-water mutual wrapping type. The invention further discloses a preparation method, the process controllability is high, and low-cost production is facilitated. The reemulsion can play a slow-release and long-acting role after intramuscular injection, the effective concentration of the antibody can be maintained in vivo for a long time, repeated medication is not needed, the stress reaction of animals is reduced, meanwhile, viruses are neutralized more thoroughly, the overall curative effect is remarkably improved, and the treatment cycle is shortened.

The invention is suitable for the technical field of gene engineering, and provides 3Ag-mi3 protein nanoparticles for preventing and treating BVD and IBR as well as a preparation method and application of the 3Ag-mi3 protein nanoparticles, the 3Ag-mi3 protein nanoparticles comprise E2-1b-mi3 fusion protein, E2-1d-mi3 fusion protein and gD-mi3 fusion protein; the amino acid sequences of the E2-1b-mi3 fusion protein, the E2-1d-mi3 fusion protein and the gD-mi3 fusion protein are respectively shown as SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6 in a sequence table. After animals are immunized by the 3Ag-mi3 protein nanoparticles, an effective immune protection effect can be generated, and the 3Ag-mi3 protein nanoparticles have a good prevention and control application prospect on bovine viral diarrhea and bovine rhinotracheitis.

The invention is suitable for the technical field of protein vaccines, and provides Zera-3Ag protein nanoparticles for preventing and treating BVD and IBR as well as a preparation method and application of the Zera-3Ag protein nanoparticles, and the Zera-3Ag protein nanoparticles comprise E2-1b-Zeraa fusion protein, E2-1d-Zeraa fusion protein and gD-Zeraa fusion protein; the amino acid sequences of the E2-1b-Zera fusion protein, the E2-1d-Zera fusion protein and the gD-Zera fusion protein are respectively shown as SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6 in a sequence table. After animals are immunized by the Zera-3Ag protein nano-particles, an effective immune protection effect can be generated, and the Zera-3Ag protein nano-particles have a good prevention and control application prospect on bovine viral diarrhea and bovine rhinotracheitis.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening, a peptide sequence KYRRQH (177080) with potential affinity for the target protein was identified. The 177080 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV Nsp5 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 177080 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that 177080 significantly inhibited PEDV infection.

The invention discloses an attapulgite composite nano-enzyme for resisting porcine viral diarrhea as well as a preparation method and application of the attapulgite composite nano-enzyme. According to the composite material, attapulgite is used as a carrier, firstly, an effective ingredient of radix isatidis is extracted through an alcohol-water mixture and loaded on the attapulgite, and then a zinc oxide-cuprous oxide heterojunction nanostructure is constructed on the surface of the attapulgite in situ by utilizing the guiding and reducing effects of the active ingredient of the radix isatidis. The composite nano enzyme obtained by the invention integrates the direct antiviral activity of radix isatidis, the enzyme-like catalytic performance of ZnO-Cu2O heterojunction and the adsorption function of attapulgite, and can efficiently inhibit intestinal pathogens such as porcine epidemic diarrhea virus and the like through the synergistic effect of triple mechanisms of adsorption enrichment, catalytic killing and traditional Chinese medicine inhibition. The material is simple in preparation process, green, safe and free of drug residues, and has wide application prospects in preparation of drugs and feed additives for preventing and treating porcine viral diarrhea.

According to the EHPA injection preparation for treating porcine viral diarrhea, Euphorbia hupehensis phenolic acid compounds (EHPA) are separated from roots of Euphorbia hupehensis for the first time and prepared into the injection preparation, after optimization, the stability of the injection preparation is high, the quality and characters of products within the shelf life are stable, the EHPA injection preparation is safe to animals, and animal experiments show that the EHPA injection preparation has good clinical application prospects. The compound has a good control effect on diarrhea caused by PEDV and / or PDCoV infection, can effectively reduce death of infected animals, and has an excellent treatment effect.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of Shuanling antidiarrheal granules and clathrate compounds thereof in preparation of antiviral drugs. According to the invention, an enterovirus infected cell model is constructed, ribavirin is taken as a positive drug, and the in-vitro antiviral effects of the Shuangling antidiarrheal granules and the volatile oil inclusion compound of the Shuangling antidiarrheal granules are preliminarily evaluated. In particular, the virus comprises RVA and / or HastV. Researches prove that the Shuangporia and poria antidiarrheal granule dry extract powder and the volatile oil clathrate compound have remarkable antiviral activity on RVA and HastV in vitro, the inhibition effect of the Shuangporia and poria antidiarrheal granule dry extract powder on RVA is superior to that of the volatile oil clathrate compound, and the inhibition effect of the volatile oil clathrate compound on HastV is superior to that of the Shuangporia and poria antidiarrheal granule dry extract powder. The invention provides a scientific basis for the application of the Shuanling antidiarrheal granule dry extract powder and the volatile oil clathrate compound in the treatment of viral diarrhea.